NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
Clinical Trials
52 trialsNCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT05619172 2025-07-24
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
Sotio Biotech Inc.
Phase 2 Terminated
NCT06024174 2025-07-22
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT04616196 2025-06-08
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Nektar Therapeutics
Phase 1/2 Completed
NCT04853043 2025-05-06
APK Mutant
University of Utah
Phase 2 Terminated
NCT04495621 2025-05-01
C-PRECISE-01
Menarini Group
Phase 1/2 Completed
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT02563002 2024-10-03
KEYNOTE-177
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03693170 2024-02-02
ANCHOR-CRC
Pierre Fabre Medicament
Phase 2 Completed
NCT02928224 2023-12-21
BEACON CRC
Pfizer
Phase 3 Completed
NCT01776307 2023-11-15
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Sumitomo Pharma America, Inc.
Phase 2 Completed
NCT01079780 2023-06-28
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04515394 2022-12-22
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
EMD Serono
Phase 2 Terminated
NCT02713373 2022-10-06
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT01001377 2022-09-21
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT02292758 2022-01-31
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT00803647 2021-10-06
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
NSABP Foundation Inc
Phase 2 Completed
NCT01075048 2021-04-08
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Daiichi Sankyo
Phase 1/2 Completed
NCT01280643 2021-03-15
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Fox Chase Cancer Center
Phase NA Terminated
NCT02953782 2021-03-01
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
Gilead Sciences
Phase 1/2 Completed
NCT00437268 2020-07-21
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00265850 2020-05-07
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00444678 2020-04-03
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
NYU Langone Health
Phase 2 Completed
NCT01228734 2020-01-28
TAILOR
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT01251536 2019-10-11
Everest2
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT01925274 2019-01-08
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
Pfizer
Phase 2 Terminated
NCT00551213 2018-08-24
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00925015 2018-08-15
Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00614393 2018-08-08
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00503685 2018-06-06
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
Eli Lilly and Company
Phase 2 Completed
NCT00686166 2018-05-18
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00326495 2017-07-24
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00154102 2017-01-30
CRYSTAL
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT00537823 2016-12-20
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Washington University School of Medicine
Phase 2 Terminated
NCT01450319 2016-11-28
MUTEX
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT01451632 2016-09-08
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Merrimack Pharmaceuticals
Phase 1 Completed
NCT01008475 2016-03-30
POSEIDON
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00271011 2015-12-03
A Study of Mitomycin C, Irinotecan, and Cetuximab
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01004159 2015-10-19
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00778830 2015-05-14
APEC
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00538291 2014-08-28
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
City of Hope Medical Center
Phase 2 Terminated
NCT00125034 2014-08-07
OPUS
Merck KGaA, Darmstadt, Germany
Phase 2 Completed